Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.28758 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Nasamon Wanlapakorn und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
To compare the reactogenicity and immunogenicity between the two‐dose mRNA COVID‐19 vaccine regimen and one or two doses of inactivated vaccine followed by an mRNA vaccine regimen in healthy children between 5 and 11 years of age, a prospective cohort study was performed at King Chulalongkorn Memorial Hospital in Thailand between March to June 2022. Healthy children between 5 and 11 years of age were enrolled and received the two‐dose mRNA COVID‐19 vaccine (BNT162b2) regimen or the inactivated (CoronaVac) vaccine followed by the BNT162b2 vaccine regimen. In addition, healthy children who received two doses of BBIBP‐CorV between 1 and 3 months prior were enrolled to receive a heterologous BNT162b2 as a third dose (booster). Reactogenicity was assessed by a self‐reported online questionnaire. Immunogenicity analysis was performed to determine binding antibodies to wild‐type SARS‐CoV‐2. Neutralizing antibodies to Omicron variants (BA.2 and BA.5) were tested using the focus reduction neutralization test. Overall, 166 eligible children were enrolled. Local and systemic adverse events which occurred within 7 days after vaccination were mild to moderate and well‐tolerated. The two‐dose BNT162b2, CoronaVac followed by BNT162b2, and two‐dose BBIBP‐CorV followed by BNT162b2 groups elicited similar levels of anti‐receptor‐binding domain (RBD) IgG. However, the two‐dose BNT162b2 and two‐dose BBIBP‐CorV followed by BNT162b2 groups elicited higher neutralizing activities against the Omicron BA.2 and BA.5 variant than the CoronaVac followed by BNT162b2 group. The CoronaVac followed by BNT162b2 group elicited low neutralizing activities against the Omicron BA.2 and BA.5 variant. A third dose (booster) mRNA vaccine should be prioritized for this group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Center of Excellence in Osteoarthritis and Musculoskeleton, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Chulalongkorn University International Medical Program (CU-MEDi), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Division of Dengue Hemorrhagic Fever Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Siriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Molecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Development Agency, NSTDA, Pathum Thani, Thailand.
ORCID-Profile: Yong Poovorawan
Zitieren
APA
Wanlapakorn, N., Kanokudom, S., Phowatthanasathian, H., Chansaenroj, J., Suntronwong, N., Assawakosri, S., Yorsaeng, R., Nilyanimit, P., Vichaiwattana, P., Klinfueng, S., Thongmee, T., Aeemjinda, R., Khanarat, N., Srimuan, D., Thatsanatorn, T., Chantima, W., Pakchotanon, P., Duangchinda, T., Sudhinaraset, N., & Poovorawan, Y. (2023). Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years. Journal of Medical Virology. https://doi.org/10.1002/jmv.28758
Vancouver
Wanlapakorn N, Kanokudom S, Phowatthanasathian H, Chansaenroj J, Suntronwong N, Assawakosri S, et al. Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years. Journal of Medical Virology. 2023. doi:10.1002/jmv.28758
BibTeX
@article{Wanlapakorn2023,
author = {Wanlapakorn, Nasamon and Kanokudom, Sitthichai and Phowatthanasathian, Harit and Chansaenroj, Jira and Suntronwong, Nungruthai and Assawakosri, Suvichada and Yorsaeng, Ritthideach and Nilyanimit, Pornjarim and Vichaiwattana, Preeyaporn and Klinfueng, Sirapa and Thongmee, Thanunrat and Aeemjinda, Ratchadawan and Khanarat, Nongkanok and Srimuan, Donchida and Thatsanatorn, Thaksaporn and Chantima, Warangkana and Pakchotanon, Pattarakul and Duangchinda, Thaneeya and Sudhinaraset, Natthinee and Poovorawan, Yong},
title = {Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.28758}
}
EUVIMED